Literature DB >> 29864539

Pre-specification of statistical analysis approaches in published clinical trial protocols was inadequate.

Lauren Greenberg1, Vipul Jairath2, Rupert Pearse3, Brennan C Kahan4.   

Abstract

OBJECTIVES: Results from randomized trials can depend on the statistical analysis approach used. It is important to prespecify the analysis approach in the trial protocol to avoid selective reporting of analyses based on those which provide the most favourable results. We undertook a review of published trial protocols to assess how often the statistical analysis of the primary outcome was adequately prespecified.
METHODS: We searched protocols of randomized trials indexed in PubMed in November 2016. We identified whether the following aspects of the statistical analysis approach for the primary outcome were adequately prespecified: (1) analysis population; (2) analysis model; (3) use of covariates; and (4) method of handling missing data.
RESULTS: We identified 99 eligible protocols. Very few protocols adequately prespecified the analysis population (8/99, 8%), analysis model (27/99, 27%), covariates (40/99, 40%), or approach to handling missing data (10/99, 10%). Most protocols did not adequately predefine any of these four aspects of their statistical analysis approach (39%) or predefined only one aspect (36%). No protocols adequately predefined all four aspects of the analysis.
CONCLUSION: The statistical analysis approach is rarely prespecified in published trial protocols. This may allow selective reporting of results based on different analyses.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analysis switching; Clinical trial; Pre-specification; Randomized controlled trial; Statistical analysis

Mesh:

Year:  2018        PMID: 29864539     DOI: 10.1016/j.jclinepi.2018.05.023

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  6 in total

1.  DEBATE-statistical analysis plans for observational studies.

Authors:  Bart Hiemstra; Frederik Keus; Jørn Wetterslev; Christian Gluud; Iwan C C van der Horst
Journal:  BMC Med Res Methodol       Date:  2019-12-09       Impact factor: 4.615

Review 2.  Estimands in published protocols of randomised trials: urgent improvement needed.

Authors:  Brennan C Kahan; Tim P Morris; Ian R White; James Carpenter; Suzie Cro
Journal:  Trials       Date:  2021-10-09       Impact factor: 2.279

3.  Access to unpublished protocols and statistical analysis plans of randomised trials.

Authors:  Vipul Jairath; Brennan C Kahan; David Campbell; Cassandra McDonald; Suzie Cro
Journal:  Trials       Date:  2022-08-17       Impact factor: 2.728

Review 4.  Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomised trials.

Authors:  Suzie Cro; Gordon Forbes; Nicholas A Johnson; Brennan C Kahan
Journal:  BMC Med       Date:  2020-05-29       Impact factor: 8.775

5.  How to design a pre-specified statistical analysis approach to limit p-hacking in clinical trials: the Pre-SPEC framework.

Authors:  Brennan C Kahan; Gordon Forbes; Suzie Cro
Journal:  BMC Med       Date:  2020-09-07       Impact factor: 8.775

6.  Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.

Authors:  David Bomze; Nethanel Asher; Omar Hasan Ali; Lukas Flatz; Daniel Azoulay; Gal Markel; Tomer Meirson
Journal:  JAMA Netw Open       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.